TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Pemmaraju N, Mead AJ, Somervaille TCP, Palandri F, Koschmieder S, Delage R, Kiladjian JJ, Benton C, Tantravahi SK, Lavi N, Yeh SP, Gomez Casares MT, Ammatuna E, McDonald A, Yoon SS, Kirito K, Devos T, Perkins A, Radinoff A, Sevindik OG, Bogdanovic A, Moskal R, Harb JG, Murray B, Jiang Q, Chopra AS, Papadopoulos EJ, Potluri J, Passamonti F

Open source

DOI: 10.1182/blood.2025032360
Published: 2026 Oct 15
Container: Blood
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2025032360,
  title = {TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.},
  author = {Pemmaraju N and Mead AJ and Somervaille TCP and Palandri F and Koschmieder S and Delage R and Kiladjian JJ and Benton C and Tantravahi SK and Lavi N and Yeh SP and Gomez Casares MT and Ammatuna E and McDonald A and Yoon SS and Kirito K and Devos T and Perkins A and Radinoff A and Sevindik OG and Bogdanovic A and Moskal R and Harb JG and Murray B and Jiang Q and Chopra AS and Papadopoulos EJ and Potluri J and Passamonti F},
  year = {2026},
  journal = {Blood},
  doi = {10.1182/blood.2025032360},
  url = {https://doi.org/10.1182/blood.2025032360}
}

RIS

TY  - JOUR
TI  - TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.
AU  - Pemmaraju N
AU  - Mead AJ
AU  - Somervaille TCP
AU  - Palandri F
AU  - Koschmieder S
AU  - Delage R
AU  - Kiladjian JJ
AU  - Benton C
AU  - Tantravahi SK
AU  - Lavi N
AU  - Yeh SP
AU  - Gomez Casares MT
AU  - Ammatuna E
AU  - McDonald A
AU  - Yoon SS
AU  - Kirito K
AU  - Devos T
AU  - Perkins A
AU  - Radinoff A
AU  - Sevindik OG
AU  - Bogdanovic A
AU  - Moskal R
AU  - Harb JG
AU  - Murray B
AU  - Jiang Q
AU  - Chopra AS
AU  - Papadopoulos EJ
AU  - Potluri J
AU  - Passamonti F
PY  - 2026
JO  - Blood
DO  - 10.1182/blood.2025032360
UR  - https://doi.org/10.1182/blood.2025032360
ER  -

APA

N, P., AJ, M., TCP, S., F, P., S, K., R, D., JJ, K., C, B., SK, T., N, L., SP, Y., MT, G. C., E, A., A, M., SS, Y., K, K., T, D., A, P., A, R., OG, S., A, B., R, M., JG, H., B, M., Q, J., AS, C., EJ, P., J, P., & F, P. (2026). TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.. Blood. https://doi.org/10.1182/blood.2025032360

Source records

pubmed · retrieved 2026-11-11T01:38:19.807Z
europe-pmc · retrieved 2026-11-11T01:38:19.845Z